Log in to save to my catalogue

Asundexian versus Apixaban in Patients with Atrial Fibrillation

Asundexian versus Apixaban in Patients with Atrial Fibrillation

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_546739

Asundexian versus Apixaban in Patients with Atrial Fibrillation

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

A randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrial fibrillation.

Alternative Titles

Full title

Asundexian versus Apixaban in Patients with Atrial Fibrillation

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_DiVA_org_uu_546739

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_546739

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2407105

How to access this item